A randomised comparison of safety and efficacy of triple therapy for 12 weeks, followed by 12 or 36 additional weeks of peginterferon alfa 2b and ribavirin in HCV patients

Authors
Category Primary study
Registry of TrialsUMIN Clinical Trials Registry
Year 2011
INTERVENTION: telaprevir plus peginterferon alfa‐2b/ribavirin for 12 weeks, followed by 12 additional weeks of peginterferon alfa 2b and ribavirin telaprevir plus peginterferon alfa‐2b/ribavirin for 12 weeks, followed by 36 additional weeks of peginterferon alfa 2b and ribavirin CONDITION: Chronic hepatitis C PRIMARY OUTCOME: sustend virologic response SECONDARY OUTCOME: virologic response at4,8,12,24 ,36,48 weeks ; Safety ( moniterd clinical and laboratory evaluation) INCLUSION CRITERIA: Genotype 1 and high virus load(5 logIU/ml < or=) IL28BSNP (rs8099917) nonTT
Epistemonikos ID: 5fc8d618f1e3d87b6e88c0748cec4f543f5bbbe7
First added on: Aug 22, 2024